SI-BONE Inc
NASDAQ:SIBN

Watchlist Manager
SI-BONE Inc Logo
SI-BONE Inc
NASDAQ:SIBN
Watchlist
Price: 13.27 USD 0.84% Market Closed
Market Cap: 556.5m USD
Have any thoughts about
SI-BONE Inc?
Write Note

SI-BONE Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SI-BONE Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
SI-BONE Inc
NASDAQ:SIBN
Cost of Revenue
-$35m
CAGR 3-Years
-55%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Cost of Revenue
-$11B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-10%
Boston Scientific Corp
NYSE:BSX
Cost of Revenue
-$4.9B
CAGR 3-Years
-9%
CAGR 5-Years
-10%
CAGR 10-Years
-8%
Stryker Corp
NYSE:SYK
Cost of Revenue
-$7.9B
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
-9%
Abbott Laboratories
NYSE:ABT
Cost of Revenue
-$18.2B
CAGR 3-Years
0%
CAGR 5-Years
-7%
CAGR 10-Years
-7%
Intuitive Surgical Inc
NASDAQ:ISRG
Cost of Revenue
-$2.6B
CAGR 3-Years
-15%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
No Stocks Found

SI-BONE Inc
Glance View

Market Cap
554.6m USD
Industry
Health Care

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 352 full-time employees. The company went IPO on 2018-10-17. The firm is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the instruments developed to enable surgeons to perform the procedure. Its iFuse system, which includes its implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based and other minimally invasive stabilization and fusion procedures. Its iFuse-3D design allows the surgeons to fill the implant with ground-up bone before implantation, which accelerates bone through-growth and biological fixation. The company also provides other technologies for its surgeons other than iFuse and iFuse-3D.

SIBN Intrinsic Value
20.78 USD
Undervaluation 36%
Intrinsic Value
Price

See Also

What is SI-BONE Inc's Cost of Revenue?
Cost of Revenue
-35m USD

Based on the financial report for Sep 30, 2024, SI-BONE Inc's Cost of Revenue amounts to -35m USD.

What is SI-BONE Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-42%

Over the last year, the Cost of Revenue growth was -44%. The average annual Cost of Revenue growth rates for SI-BONE Inc have been -55% over the past three years , -42% over the past five years .

Back to Top